Browse Guides  internal medicine  neurology

Stroke

Prevalence
Clinical features
Investigations
Therapy
Prevention
Prognosis
Prevention

Acute ischaemic stroke or transient ischaemic attack

Give an ACE inhibitor a

Why?

  • Patients at high-risk for cardiovascular disease who take ramipril are less likely to die, have a stroke, myocardial infarction, cardiac arrest or develop heart failure. a
  • Many patients stop therapy, particularly due to cough. a

Ramipril reduces death and cardiovascular complications in patients at high-risk for cardiovascular disease

Patient a Treatment Comparison Outcome CER RRR
(95% CI)
NNT
(95% CI)
previous stroke, MI or peripheral vascular disease and at least one other cardiovascular risk factor ramipril placebo death from any cause
at 5 years
12% 15%
(5% to 24%)
55
(32 to 180)
      myocardial infarction
at 5 years
12% 19%
(9% to 28%)
44
(28 to 99)
      stroke
at 5 years
4.9% 30%
(15% to 43%)
68
(44 to 150)
      heart failure
at 5 years
12% 22%
(12% to 31%)
39
(26 to 77)
      cardiac arrest
at 5 years
1.3% 36%
(4% to 58%)
220
(120 to 2400)
      discontinued therapy permanently
at 5 years
31% -6%
(-13% to -0.086%)
-52
(-3500 to -26)
      treatment discontinued due to cough
at 5 years
1.9% -300%
(-410% to -220%)
-18
(-22 to -16)

Expiry date: October 2003
Levels of Evidence used in grading these guides

Author   CM   Ball
Reviewer   G  Donnan
CAT Writers   CJ   Wotton , N   Shenker , CM   Ball